Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.45 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.45 |
| ▸ | GGT1 | P19440 | 2/20 | 0.44 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704707 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL14677435 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL5704713 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL609262 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13224565 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13746294 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL502878 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL3471145 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL13224526 | 1.00 | SLC7A5 (0.54) | SLC7A5SLC1A1FOLH1SLC1A3SLC1A2 | |
| SCHEMBL12900073 | 0.85 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 326 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274126-B2 | pH-sensitive cyclic peptides | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2022-03-15 | — | — | US | claimed |
| EP-2994154-B1 | ANTIMICROBIAL PEPTIDE | ACADEMISCH ZIEKENHUIS LEIDEN (NL) | 2020-02-26 | — | — | EP | claimed |
| EP-3432908-A1 | pH-SENSITIVE PEPTIDES | Rhode Island Council on Postsecondary Education (US) | 2019-01-30 | — | — | EP | claimed |
| EP-3335720-A1 | C-DI-GMP BINDING PEPTIDES | Universität Basel (CH) | 2018-06-20 | — | — | EP | claimed |
| WO-2017165452-A1 | pH-SENSITIVE PEPTIDES | RHODE ISLAND COUNCIL ON POSTSECONDARY EDUCATION (US) | 2017-09-28 | — | — | WO | claimed |
| US-9650618-B2 | Endonucleases | BIOTEC PHARMACON ASA (NO) | 2017-05-16 | — | — | US | claimed |
| EP-2814954-B1 | ENDONUCLEASES | BIOTEC PHARMACON ASA (NO) | 2017-04-05 | — | — | EP | claimed |
| US-20160355798-A1 | ENDONUCLEASES | BIOTEC PHARMACON ASA (NO) | 2016-12-08 | — | — | US | claimed |
| US-9422595-B2 | Endonucleases | BIOTEC PHARMACON ASA (NO) | 2016-08-23 | — | — | US | claimed |
| EP-2814954-A1 | ENDONUCLEASES | Biotec Pharmacon ASA (NO) | 2014-12-24 | — | — | EP | claimed |
| US-7483732-B2 | Magnetic resonance imaging of a medical device and proximate body tissue | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-01-27 | — | — | US | claimed |
| EP-1735629-A1 | MAGNETIC RESONANCE IMAGING OF A MEDICAL DEVICE AND PROXIMATE BODY TISSUE | Boston Scientific Limited, an Irish company (BB) | 2006-12-27 | — | — | EP | claimed |
| WO-2005101045-A1 | MAGNETIC RESONANCE IMAGING OF A MEDICAL DEVICE AND PROXIMATE BODY TISSUE | BOSTON SCIENTIFIC LIMITED, AN IRISH COMPANY (BB) | 2005-10-27 | — | — | WO | claimed |
| US-20050240098-A1 | Magnetic resonance imaging of a medical device and proximate body tissue | BOSTON SCIENTIFIC SCIMED, INC. | 2005-10-27 | — | — | US | claimed |
| US-20040002143-A1 | Method of constructing amino acid producing bacterial strains, and method of preparing amino acids by fermentation with the constructed amino acid producing bacterial strains | AJINOMOTO CO., INC. (JP) | 2004-01-01 | — | — | US | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-6310093-B1 | ADMINISTERING, IN AMOUNT EFFECTIVE TO REDUCE DAMAGE TO NEURONAL CELLS, COMPOUND WHICH SELECTIVELY INHIBITS EXTRACELLULAR GLUTAMINASE RELATIVE TO GLUTAMINASE PRESENT IN INTACT CELLS AND IS IMPERMEABLE TO INTACT CELL MEMBRANES | ELAN PHARMACEUTICALS, INC. | 2001-10-30 | — | — | US | claimed |
| EP-1033407-A1 | PROCESS FOR CONSTRUCTING AMINO ACID-PRODUCING BACTERIUM AND PROCESS FOR PRODUCING AMINO ACID BY FERMENTATION METHOD WITH THE USE OF THE THUS CONSTRUCTED AMINO ACID-PRODUCING BACTERIUM | Ajinomoto Co., Inc. (JP) | 2000-09-06 | — | — | EP | claimed |
| WO-1999009825-A1 | METHOD OF PREVENTING NEURONAL DEATH | ELAN PHARMACEUTICALS, INC. (US) | 1999-03-04 | — | — | WO | claimed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274126-B2 | pH-sensitive cyclic peptides | VIP, PHLPP1, PHLPP2 | SLC7A5 227/4885SLC1A1 2871/4885FOLH1 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.